Blood pressure levels and stroke: J-curve phenomenon?

Current Hypertension Reports

Volumn 15, Issue 6, 2013, Pages 575-581

  Malyszko, Jolanta ^a   Muntner, Paul ^b   Rysz, Jacek ^c   Banach, Maciej ^c  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Blood pressure; Cerebrovascular event; Hypertension; J curve relationship; Stroke

Indexed keywords

ANTIHYPERTENSIVE AGENT; IRBESARTAN;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG FATALITY; GERIATRIC PATIENT; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK POPULATION; HUMAN; HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; STROKE PATIENT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

AGING; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; RISK FACTORS; STROKE;

EID: 84890130510     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-013-0402-z     Document Type: Article

References (65)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6-245.
2. Piotrowski G, Banach M, Gerdts E, Mikhailidis DP, Hannam S, Gawor R, et al. Left atrial size in hypertension and stroke. J Hypertens. 2011;29(10):1988-93.
3. Mukherjee D, Patil CG. Epidemiology and the global burden of stroke. World Neurosurg. 2011;76:S85.
4. Haley WE, Roth DL, Kissela B, Perkins M, Howard G. Quality of life after stroke: a prospective longitudinal study. Qual Life Res. 2011;20(6):799-806.
5. Brenner DA, Zweifler RM, Gomez CR, Kissela BM, Levine D, Howard G, et al. Awareness, treatment, and control of vascular risk factors among stroke survivors. J Stroke Cerebrovasc Dis. 2010;19(4):311-20.
6. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit. 2009;15(12):MS1-5.
7. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765.
8. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827.
9. Banach M, Aronow WS. Hypertension therapy in the older adults-do we know the answers to all the questions? The status after publication of the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. J Hum Hypertens. 2012;26(11):641-3.
10. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255.
11. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757.
12. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903.
13. Seshadri S, Wolf PA, Beiser A, et al. Elevated midlife blood pressure increases stroke risk in elderly persons: the Framingham Study. Arch Intern Med. 2001;161:2343.
14. Barylski M, Małyszko J, Rysz J, MyÅliwiec M, Banach M. Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci. 2011;7(6):1055-66.
15. Athyros VG, Giouleme O, Ganotakis ES, Elisaf M, Tziomalos K, Vassiliadis T, et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci. 2011;7(5):796-805.
16. Feigin VL, Barker-Collo S, Parag V, et al. Auckland Stroke Outcomes Study. Part 1: gender, stroke types, ethnicity, and functional outcomes 5 years poststroke. Neurology. 2010;75:1597.
17. Knoflach M, Matosevic B, Rücker M, et al. Functional recovery after ischemic stroke-a matter of age: data from the Austrian Stroke Unit Registry. Neurology. 2012;78:279.
18. Howard VJ, Woolson RF, Egan BM, Nicholas JS, Adams RJ, Howard G, et al. Prevalence of hypertension by duration and age at exposure to the stroke belt. J Am Soc Hypertens. 2010;4(1):32-41.
19. Steiner T, Mendoza G, De Georgia M, et al. Prognosis of stroke patients requiring mechanical ventilation in a neurological critical care unit. Stroke. 1997;28:711.
20. Kammersgaard LP, Jørgensen HS, Reith J, et al. Short- and long-term prognosis for very old stroke patients. The Copenhagen Stroke Study. Age Ageing. 2004;33:149.
21. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303:2043.
22. Vasan RS, Larson MG, Leip EP, et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001;358:1682.
23. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002;287:1003.
24. Song YM, Sung J, Lawlor DA, et al. Blood pressure, haemorrhagic stroke, and ischaemic stroke: the Korean national prospective occupational cohort study. BMJ. 2004;328:324.
25. Siebert J, Gutknecht P, Molisz A, Trzeciak B, Nyka W. Hemodynamic findings in patients with brain stroke. Arch Med Sci. 2012;8(2):371-4.
26. Vermeer SE, Longstreth Jr WT, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol. 2007;6:611.
27. Prabhakaran S, Wright CB, Yoshita M, et al. Prevalence and determinants of subclinical brain infarction: the Northern Manhattan Study. Neurology. 2008;70:425.
28. Das RR, Seshadri S, Beiser AS, et al. Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study. Stroke. 2008;39:2929.
29. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895.
30. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010;375:938.
31. Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M. The rise and fall of hypertension: lessons learned from Eastern Europe. Curr Cardiovasc Risk Rep. 2011;5(2):174-9.
32. Mercando AD, Lai HM, Aronow WS, Kalen P, Desai HV, Gandhi K, et al. Reduction in atherosclerotic events: a retrospective study in an outpatient cardiology practice. Arch Med Sci. 2012;8(1):57-62.
33. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:227.
34. Seneff S, Wainwright G, Mascitelli L. Is the metabolic syndrome caused by a high fructose, and relatively low fat, low cholesterol diet? Arch Med Sci. 2011;7(1):8-20.
35. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-357.
36. Aronow WS, Banach M. Ten most important things to learn from the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Blood Press. 2012;21(1):3-5.
37. Banach M, Michalska M, Kjeldsen SE, Małyszko J, Mikhailidis DP, Rysz J. What should be the optimal levels of blood pressure: does the J-curve phenomenon really exist? Expert Opin Pharmacother. 2011;12(12):1835-44.
38. Stewart IM. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet. 1979;1:861-5.
39. Banach M, Aronow WS. Blood pressure j-curve: current concepts. Curr Hypertens Rep. 2012;14(6):556-66.
40. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;1(8533):581-4.
41. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997;278:212.
42. •• Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887. The first randomized controlled trial which confirmed that we should have always treated elderly patients with hypertension, as it significantly improved cardiovascular and mortality outcomes.
43. Staessen JA, Fagard R, Thijs L, et al. Subgroup and per-protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Arch Intern Med. 1998;158:1681.
44. Tuomilehto J, Rastenyte D, Birkenhäger WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med. 1999;340:677.
45. Banach M, Rysz J. Current problems in hypertension and nephrology. Expert Opin Pharmacother. 2010;11(16):2575-8.
46. Gharipour M, Kelishadi R, Khosravi A, Shirani S, Masjedi M, Sarrafzadegan N. The impact of a community trial on the pharmacological treatment in the individuals with the metabolic syndrome: findings from the Isfahan Healthy Heart Program, 2001-2007. Arch Med Sci. 2012;8(6):1009-17.
47. Banach M, Kjeldsen SE, Narkiewicz K. Controversies in hypertension treatment. Curr Vasc Pharmacol. 2010;8(6):731-2.
48. Banach M, Hering D, Narkiewicz K, Mysliwiec M, Rysz J, Malyszko J. Lipids, blood pressure, kidney-what was new in 2012? Int J Pharmacol. 2012;8:659-78.
49. Somes GW, Pahor M, Shorr RI, et al. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med. 1999;159:2004.
50. Zhang Y, Zhang X, Liu L, Zanchetti A. Is a systolic blood pressure target < 140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomised FEVER trial. Eur Heart J. 2011;32:1500-8.
51. Vokó Z, Bots ML, Hofman A, et al. J-shaped relation between blood pressure and stroke in treated hypertensives. Hypertension. 1999;34:1181.
52. Boutitie F, Gueyffier F, Pocock S, et al. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data. Ann Intern Med. 2002;136:438.
53. Dorresteijn JA, van der Graaf Y, Spiering W, Grobbee DE, Bots ML, Visseren FL, et al. Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease: J-curve revisited. Hypertension. 2012;59:14-21.
54. Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J. 2010;31:2897-908.
55. th September 2013). Very important observational study made in the stroke belt area of US. It showed that for all patients above 55 we should always consider SBP level below 140 mmHg. It did not also show any J-curve relation between SBP and stroke incidence, and rather linear association (the lower the better relation).
56. The ACCORD Study Group. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. N Engl J Med. 2010;362:1575-85.
57. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-59.
58. Berl T, Hunsicker LG, Lewis JB, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol. 2005;16:2170-9.
59. Nilsson PM. ACCORD and risk-factor control in Type 2 diabetes. N Engl J Med. 2010;362:1628-30.
60. Systolic Blood Pressure Intervention Trial (SPRINT). ClinicalTrials.gov Identifier: NCT01206062.
61. •• Zanchetti A, Liu L, Mancia G, Parati G, Grassi G, Stramba-Badiale M et al. Blood Pressure and LDL-Cholesterol targets for prevention of recurrent strokes and cognitive decline in the elderly hypertensive patient. Design of the European Society of Hypertension - Chinese Hypertension League stroke in hypertension on optimal treatment (ESH-CHL-SHOT) randomized trial. J Hypertens 2014; (in press). It is important multinational and multicentre study, which may finally answer the question on the optimal blood pressure levels in patients after stroke/TIA, as well as the occurrence of J-curve shaped relation in this group of patients (or lack of such association).
62. Zanchetti A, L. Liu, Mancia G, Parati G, Grassi G, Stramba-Badiale M et al. Blood pressure and LDL-Cholesterol targets for prevention of strokes and cognitive decline in the hypertensive patient. Review of available trial evidence. J Hypertens 2014; (in press).
63. Makariou S, Liberopoulos E, Florentin M, Lagos K, Gazi I, Challa A, et al. The relationship of vitamin D with non-traditional risk factors for cardiovascular disease in subjects with metabolic syndrome. Arch Med Sci. 2012;8(3):437-43.
64. Michalska M, Rysz J, Pencina MJ, Zdrojewski T, Banach M. The knowledge and awareness of hypertension among patients with hypertension in Central Poland: A pilot registry. Angiology. 2013. doi: 10.1177/0003319713489166.
65. Sundström J, Sheikhi R, Ostgren CJ, Svennblad B, Bodegård J, Nilsson PM, et al. Blood pressure levels and risk of cardiovascular events and mortality in type-2 diabetes: cohort study of 34009 primary care patients. J Hypertens. 2013;31(8):1603-10.